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Introduction 
 
1.1 Oral Squamous Cell Carcinoma (OSCC) 
Oral Squamous Cell Carcinoma (OSCC) is the most common malignant tumor of the oral 
cavity. It represents the majority of head and neck cancers with more than half million 
patients being affected each year worldwide [1]. More than 90% are squamous cell 
carcinomas which are mostly attributed to exogenous factors such as tobacco smoking and 
heavy alcohol consumption. Advances in cancer research have provided new information 
on the cellular and molecular processes in carcinogenesis. This also has lead to the 
identification of biological markers and effective treatment options. The long-term 
survival rates, however, remain low and many individuals are affected. 
 
1.1.1 OSCC epidemiology 
OSCC is the eighth most common cancer in the world, with the highest prevalence among 
men (5-year prevalence in men: 401,075) [2]. According to Ferlay et al. the worldwide cases 
of oral cancer in 2008 in both sexes were about 263,000 (2.1% of the total cancers), the 
incidence rate was 3.9 per 100,000 persons and approximately 127,000 cases were fatal. 
According to the American Cancer society the incidence of OSCC is higher in developed 
countries when compared to developing countries, but the mortality rates remain higher 
in developing countries. In developing countries the incidence of OSCC is 107,700 in males 
and the estimated deaths are 61,200 [3].  
In south-central Asia, OSCC is one of the third most frequent types of cancer. In India the 
incidence rate is 12.6 per 100 000 population, and in other countries of Asia OSCC remains 
one of the most common cancers [4, 5]. Of interest, the incidence rate remains high in 
	   6	  
several developed countries such as Denmark, Poland, Germany, Scotland, and also in 
Australia, Japan, New Zealand and the USA [6, 7]. 
 
1.1.2 Survival Rates 
The 5-year survival rate has been relatively low for OSCC despite advancement in 
diagnosis and treatment. According to the Surveillance, Epidemiology and End Results 
Program the overall 5-year relative survival is 62.2%. The 5-year survival rate of late-stage 
OSCC (distant, cancer has metastasized) is only 20% and it is approximately 82% for early 
stage OSCC (localized tumor, confined to primary site) [8]. In USA from 1983 to 2006, the 
five-year survival rate has increased from 52.5% to 60.8% within the time period [9].  
Data from the World Health Organization showed a similar negative trend in the survival 
rates between 2005-2010 in some countries (e.g., Brazil, Egypt, Germany, Japan, 
Netherlands, Poland, United Kingdom) [10] where the number of deaths has increased. 
 
1.1.3 Demographic and Anatomical sites 
OSCC arises from mucosa lining of the oral cavity or from the lips. The most common type 
is squamous cell carcinoma, and the histological grade can vary from well-differentiated 
keratinizing to undifferentiated non-keratinizing with a high tendency to metastasize.   
In the United States the median age at diagnosis for cancer of the oral cavity is 64.5 years 
of age [11]. The tongue remains the main site of OSCC [12-16], affecting particularly the 
lateral posterior border, in older males individuals [17]. Interestingly, a new trend 
emerged during the last 20 years; the rate of OSCC (especially tongue cancer) increased in 
younger patients without any apparent and common risk factor such as tobacco or alcohol 
consumption [18, 19]. The increased trend of OSCC in younger patients merits further 
investigation. Data from 2006-2010 show that the total percentage of cancer of the tongue 
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who occurred in people younger than 45 years old is 7.5% whereas the median age at 
diagnosis for tongue cancer is 61 years of age [20]. The other most involved sites are the 
lips (17%) and the floor of the mouth (14%). Lip cancer, especially the lower lip, is 
typically observed in people who are exposed to sunlight (e.g., fishermen, farmers, skiers 
and windsurfers) [21].  
 
1.1.4 Diagnosis 
The clinical appearance of OSCC is variable and requires an expert eye to recognize its 
features. Early lesions may appear as red oral mucosa failing to heal within two weeks, or 
as a persistent lump with spontaneous bleeding or ulceration [22]. Lesions may appear 
flat, raised, exophytic or ulcerated without any initial symptoms. Over time patients may 
complain of difficulties chewing, limited tongue movement or an abnormal sensation 
secondary to swelling. After the cancer growth, more symptoms occur and include 
bleeding, paresthesia, mobile teeth (when the tumor invades the bone), and induration 
and fixation of soft tissues; only one third are diagnosed with localized tumors [23]. Any 
suspicious and persistent lesion should be followed up by the clinician and biopsied [24].  
 
1.1.5 The malignant progression 
Normal cells transform into preneoplastic cells and then to cancer after a series of clinical 
and histopathological stages involving genetic and molecular changes. These stages are 
clinically represented by manifestations on oral mucosa, such as leukoplakia, 
erythroplakia or leukoerythroplakia, and they all represent a predictive factor of 
malignant transformation [25]. 
The multi-step progression of cancer involves a combination of acquired and inherited 
alterations in the DNA sequence. Genetic changes in keratinocytes cause a progressive 
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acquisition of a malignant phenotype from premalignant to cancer, characterized by 
invasion across the epithelial basement membrane and eventual metastasis. The 
overexpression of oncogenes causes a disruption in the cell cycle driving to abnormal cell 
proliferation [2], while the expression of the tumor suppressor genes, especially the 
proteins p53 and p16 in the dysplastic epithelium are significant markers to detect 
potentially malignant lesions in the oral cavity [26]. 
Risk factors can lead to genetic and epigenetic alterations; the most observed cases of 
mutation of these genes are present in people from Asia due to the tobacco chewing and 
betel quid [27, 28]. Furthermore, epigenetic may cause an alteration of gene expression 
through aberrant DNA methylation, histone modifications and expression of microRNAs 
[29]. 
 
 
Dionne KR, Warnakulasuriya S, Zain RB, Cheong SC. Potentially malignant disorders of the oral cavity: current practice 
and future directions in the clinic and laboratory. Int J Cancer. 2015 Feb 1;136(3):503-15.  
 
1.1.6 Oral potentially malignant lesions (OPML) 
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OPML comprise leukoplakia, erythroplakia, oral lichen planus and oral submucous 
fibrosis. These lesions are characterized by sequential accumulation of molecular changes 
that can lead to dysplasia (mild, moderate or severe) and then to frank invasive carcinoma 
[30]. 
Oral Lichen Planus (OLP) is an immuno-mediated inflammatory condition of the oral 
mucosa [31]. It occurs in 1 to 2 % of adults and may be idiopathic or associated with a 
variety of systemic and local conditions. OLP usually affects the buccal mucosa and 
tongue bilaterally, and can present with three distinct forms: reticular/keratotic (classic), 
erosive/erythematous, and ulcerative forms. Less than 1% of OLP evolve in OSCC [32, 33]. 
Oral Leukoplakia (OL) is a white lesion that can affect any site of the oral cavity, and its 
diagnosis it is made by the exclusion of the other known diseases. The malignant 
transformation rate of all leukoplakias is 9-37%. There are three clinical different type of 
leukoplakia (the homogeneous, the non homogeneous and the verrucous type); the most 
aggressive is the proliferative verrucous type (60-100% of proliferative leukoplakias 
develop carcinoma) [34]. The risk of malignant transformation is meanly correlated to the 
degree of histological dysplasia (mild, moderate or severe) that represents the histological 
step of the epithelial malignant transformation. However, dysplasia has limited prognostic 
value. Nowadays, there are not specific markers that can predict the probability of 
malignant progression from dysplatic lesions to cancer. Some OL can transform into 
cancer after a series of progressing genetic alterations. OL that transformed into OSCC are 
called progressive OL. The multi-step progression involves a combination of acquired and 
inherited alterations in the DNA sequence that can lead to OSCC. 
According to the WHO definition oral erythroplakia is defined as “any lesion of the oral 
mucosa that presents as bright red velvety plaques which cannot be characterized 
clinically or pathologically as any other recognizable condition”. The risk of malignant 
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transformation of erythroplakia is the highest between the others premalignant forms 
(90%). This lesion presents as red plaques that can be depressed or flat, and they occur 
mainly on the floor of the mouth, the soft palate and the ventral tongue [35]. 
Oral submucous fibrosis is a condition characterized by a fibrous aspect, a significant 
morbidity with pain and reduced oral opening which may affect any site of the oral cavity 
[36]. It is associated with areca nut chewing especially in Southeast Asia and the reported 
risk of malignant transformation varies from 2.3-7.6% [37]. 
 
1.2 MicroRNAs 
Mature microRNAs (miRNAs) are short, single-stranded noncoding RNAs of 21–24 
nucleotides in length that regulate gene expression post-transcriptionally by degrading or 
repressing mRNA. Specifically, miRNAs associate to their target mRNAs by base-pairing 
to partially complementary sites, usually located in the 3’untranslated region (3’UTR) [38, 
39]. A single miRNA can regulate the translation of multiple genes, thus it can modulate 
the expression of multiple proteins. 
MiRNAs can influence numerous signaling cascades and biological networks, including 
cell proliferation, differentiation, development, metabolism, apoptosis, migration, 
senescence and response to stress. 
MiRNAs play an important role in cancer because they regulate the expression of tumor-
suppressors genes and oncogenes. In fact, miRNA expression profiles are often altered in 
malignant cells, being down- or up-regulated when compared with those in normal 
tissues. The identification of miRNAs that have an oncogenic-like effect and their 
signature for every specific cancer represent a novel challenge in cancer research.  
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A comprehensive understanding of the role of miRNAs during the pathogenesis of cancer, 
and the identification of miRNA profiles specific for all tumors, will offer new opportunity 
for diagnostic, prognostic, and therapeutics. 
 
1.2.1. MiRNA biogenesis and role 
The biogenesis of miRNAs begins with the transcription inside the nucleus of the pri-
miRNA by the RNA polymerase II [40]. The pri-miRNA then is cropped by the 
microprocessor complex into a 70 nt hairpin called pre-miRNA [41]. The pre-miRNA is 
then exported in the cytoplasm where it is cleaved by the RNAse Dicer in two short 
sequences of nucleotides and one of them is incorporated into the RNA-induced silencing 
complex (RISC) [42, 43].  The mature miRNA targets the mRNAs via sequence 
complementarity, resulting in the degradation or translation repression of the mRNA. 
MiRNAs act as negative regulators of gene expression and are involved in tumorigenesis 
by targeting tumor-suppressor genes or oncogenes directly or indirectly. In general, 
miRNAs are differently and abnormally expressed in cancer cells compared to normal 
tissues, and this different expression is correlated to the development of the tumor, in 
particular it is correlated to the expression or deletion of genes involved in tumor growth 
[44]. 
The identification of miRNAs that are potential tumor-suppressors (tumor-suppressor 
miRNAs) or oncogenes (oncogenic miRNAs) may lead to the discovery of a new class of 
potential biomarkers for tumors. For example, a loss of expression of tumor-suppressor 
miRNAs may lead to elevated levels of the protein products of target oncogenes, and the 
overexpression of oncogenic miRNAs may reduce the levels of protein products of target 
tumor-suppressor genes [45]. Oncogenic miRNAs are overexpressed in the initial phases 
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of the tumor growth and their number increases during the progression of the tumor, 
while tumor-suppressor miRNAs are under-expressed. 
The expression profiles of miRNAs that act as tumor-suppressors are usually altered in 
many cancers. Their reduction accelerates the oncogenic transformation through the 
deregulation of target oncogenes, while their overexpression indicates that miRNAs can 
halt the cancer cell growth, or induce apoptosis [46]. 
 
 
 
 
1.2.2. MiRNA in OPML  
Xiao et al. reported 24 over-expressed and 9 under-expressed miRNAs in 7 malignantly 
transformed OLs compared to 20 non-progressive OLs using human oral leukoplakia cell 
line [47]. Yang et al. found 12 over-expressed and 13 under-expressed miRNAs in 8 
progressive OLs compared to 7 non-progressive OLs in saliva samples [48]. De Sarkar et 
al. showed that only miR-31 is over-expressed both in gingival buccal SCC and OLs using 
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samples from biopsies [49]. However, the most consistent article that describes a miRNA 
signature associated to progressive OPML is the study of Cervigne et al. [50]. They 
examined the miRNA expression in 29 OLs that progressed to OSCC compared to 4 non-
progressive OLs and 7 normal tissues, and they found a large number of altered miRNAs. 
In particular, miR-21, miR-181b and miR-345 showed an increased expression during the 
progression to OSCC. The authors showed that some of the genetic alterations in OSCC 
are earlier expressed in the same-site premalignant lesion. Moreover, the role of miR-345 is 
still not well understood, however it seems to under-expressed the BAG3 expression, an 
anti-apoptotic molecule. MiR-345 was over-expressed both in progressive OLs and OSCC.   
 
1.2.3. MiRNA in OSCC and metastasis 
MiRNAs can be used as prognostic factors in patients with OSCC. In fact, the TNM 
staging is not always accurate, thus it is important to correlate biomarkers, such as 
miRNAs, to the prognosis of patients with cancer. MiRNAs could also be used as 
biomarkers for the invasive behavior of OSCC. Some articles described the expression of 
tumor-suppressor miRNAs: miR-138 is under-expressed in cell culture of OSCC 
metastasis; and miR-491-5p was found under-expressed in invasive OSCC cells, 
suppressing migration, invasion and metastasis of OSCC cells. Thus, MiR-491-5p is found 
decreased in advanced OSCC and acts as a metastatic suppressor [51].  
The role of oncogenic miRNAs is well described in novel findings: oncogenic miR-181 is 
increased in lymph node metastasis and vascular invasion enhancing cell mobility; miR-
211 is over-expressed in nodal metastasis and vascular invasion of OSCC with poor 
prognosis [52, 53].  
Furthermore, miR-134 was associated with nodal metastasis and mortality of patients with 
oral cancer; high expression of miR-196a was associated with tumor recurrence, nodal 
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metastasis, and mortality; a significant association was found between miR-126 expression 
and tumor progression, nodal metastasis, vessel density, and poor prognosis in OSCC 
cases [54]. MiR-21 is an established oncogenic miRNA that targets tumor-suppressing 
genes TPM1 and PTEN [55]. Mir-21 was found over-expressed in SCC of the tongue, and 
in progressive oral OLs. This oncogenic miRNA promotes the tumor invasion of SCC of 
the tongue via the Wnt/β-catenin pathway by targeting tumor suppressor DKK2 [56]. 
MiR-21 was also involved in EMT in human bronchial epithelial cells and hepatocytes, 
while miR-375 facilitates EMT in cervical cancer cells and breast cancer cells [57, 58].  
 
1.3 N-glycosilation gene DPAGT1 
Protein N-glycosylation is one of the most abundant posttranslational modifications in 
biology. N-glycosylation controls a broad spectrum of cellular functions that are vital for 
development and homeostasis, including cell– cell and cell– matrix adhesion, cell 
proliferation, cell survival and immune system responses [59]. Dysregulated N-
glycosylation is a common theme in disease, including a prevalent association with cancer. 
In tumors of epithelial origin (carcinomas), cancer progression is associated with dramatic 
changes in cell– cell or E-cadherin-mediated adhesion, as well as aberrant organization of 
cell polarity and cytoskeleton architecture [60].   
N-Glycosylation is initiated in the endoplasmic reticulum (ER) by the dolichol phosphate-
dependent N –acetylglucosamine 1-phospho-transferase (GPT), encoded by the DPAGT1  
gene [61]. Cell– cell adhesion directs cytoskeletal dynamics to establish and maintain 
cellular polarity, which ultimately determines accurate tissue architecture. Dysregulated 
cell adhesion is a hallmark of many diseases, most notably cancer. Interestingly, 
modification of key adhesion and cytoskeletal-regulating proteins with N -glycans 
controls their activity, and thus dysregulated N-glycosylation may contribute to altered 
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adhesive properties observed in disease [62]. 
Many epithelial cancers display loss of E-cadherin, and E-cadherin is commonly 
downregulated in tumors by transcriptional repressors such as SLUG, SNAIL, TWIST and 
ZEB [63]. However, in some cancers, notably a major subset of OSCCs, E-cadherin is not 
lost. Rather, due to overexpression of DPAGT1, E-cadherin is highly modified with 
complex N -glycans and unable to form mature cell– cell contacts [64]. This suggests that 
in OSCC, and most likely in other epithelial tumors that maintain E-cadherin expression, 
N-glycosylation is a key determinant of reduced E-cadherin adhesion. 
 
1.4 Epithelial-Mesenchymal Transition (EMT) 
The epithelial-mesenchymal transition (EMT) refers to a series of biological events that 
allows epithelial cells to lose their differentiated features, including cell-cell adhesion, 
planar, apical-basal polarity and lack of motility, and assume mesenchymal phenotypes, 
including enhanced motility, invasiveness, elevated resistance to apoptosis, and increased 
production of extracellular matrix (ECM) components [65]. EMTs can be induced by a 
variety of signaling pathways that converge on a few key families of transcription factors, 
including the zinc-finger protein Snail (Snail/Slug), ZEB (ZEB1/ZEB2), and basic helix-
loop-helix factors, such as Twist [66]. Activation of these transcription factors leads to the 
repression of E-cadherin as well as other cytoskeletal and cell-surface proteins. The final 
stages of the EMT are characterized by downregulation of E-cadherin and cytokeratin and 
up-regulation of mesenchymal-specific markers, such as vimentin and fibronectin [67]. 
Specific miRNAs have been described with the regulation of EMT. In particular the miR-
200 family targets transcription factors ZEB1 and ZEB2. As ZEB factors are EMT inducers, 
the consequence of miR-200 overexpression is the reduced expression of ZEB factors and 
subsequent epithelial differentiation [68]. Also miR-205 was found downregulated in cells 
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that had undergone EMT [69]. Together these miRNAs regulate the expression of ZEB 
factors. The inhibition of the miRNA could be sufficient to induce EMT. In OSCC the miR-
200c expression was found significantly decreased in the regional lymph node metastasis 
and the miRNA have the ability to block the tumourigenicity and invasion of OSCC cell 
lines [70]. Together miR-200c and miR-205 are associated with poor prognosis of OSCC 
[71]. On the other hand, the ectopic expression of these miRNAs could initiate the 
Mesenchymal to Epithelial Transition [72] in node metastasis reprogramming the gene 
expression and the formation of adherent junctions.  
 
 
 
 
 
2. Aim of the research 
The aim of the research was to identify the expression profiles of miRNAs in progressive 
and non-progressive OPML as well as compare miRNA different expression in metastatic 
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OSCC versus non-metastatic OSCC. Furthermore, the study investigates which miRNAs is 
related to the development of lymph node metastasis and their expression in oral 
presurgical biopsies. Moreover, the research wants to investigate the role of miRNAs in 
OSCC cell lines, especially related to N-glycosilation gene DPAGT1 and EMT. 
 
 
3. Materials and Methods 
 
3.1 MiRNA in OPML and OSCC 
3.1.1 Case selection 
The samples were obtained from the files of Anatomic Pathology Section at the Bellaria 
Hospital of the Department of Biomedical and Neuromotor Sciences of the University of 
Bologna were retrieved. All tissue samples were formalin-fixed paraffin-embedded 
(FFPE). The following cases were selected for the present study: 
 
- 26 non-metastatic OSCC of which 19 of females patients and 7 of males with a 
mean age of 69 years. Five tumors were in the buccal mucosa, 3 in the floor of 
the mouth, 9 in the gingiva, 9 in the tongue. Nine OSCC were well 
differentiated, 10 were moderately differentiated, 7 were poorly differentiated. 
T1 tumors were 14, and T2 were 12. Presurgical biopsies of the tumors were 
obtained prior to the surgical intervention.   
 
Case Age / Sex Site Diagnosis Follow-up 
1 93/F Buccal Mucosa WD-OSCC T2N0 
2 66/F Gingiva WD-OSCC T1N0 
3 50/M Buccal Mucosa MD-OSCC T1N0 
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4 59/F Tongue WD-OSCC T1N0 
5 70/F Buccal Mucosa PD-OSCC T1N0 
6 74/F Gingiva PD-OSCC T1N0 
7 59/M Floor of the 
mouth 
PD-OSCC T1N0 
8 64/F Tongue PD-OSCC T1N0 
9 64/F Buccal Mucosa WD-OSCC T2N0 
10 91/M Gingiva WD-OSCC T2N0 
11 67/M Gingiva WD-OSCC T2N0 
12 76/M Tongue WD-OSCC T2N0 
13 74/F Gingiva PD-OSCC T1N0 
14 89/F Tongue WD-OSCC T2N0 
15 81/F Gingiva MD-OSCC T2N0 
16 52/F Gingiva MD-OSCC T2N0 
17 87/F Gingiva MD-OSCC T2N0 
18 65/F Floor of the 
mouth  
MD-OSCC T1N0 
19 63/F Tongue MD-OSCC T1N0 
20 35/F Tongue MD-OSCC T1N0 
21 51/M Tongue MD-OSCC T1N0 
22 72/F Tongue WD-OSCC T1N0 
23 79/F Buccal mucosa MD-OSCC T1N0 
24 76/F Floor of the 
mouth 
PD-OSCC T2N0 
25 65/F Tongue WD-OSCC T2N0 
26 69/M Gingiva MD-OSCC T2N0 
 
 
- 26 metastatic OSCC of which 13 females patients and 13 males with a mean age 
of 68 years. Four tumors were in the buccal mucosa, 1 were in the palate, 6 were 
in the gingiva, 15 were in the tongue. Three OSCC were well differentiated, 16 
were moderately differentiated, 7 were poorly differentiated. T1 tumors were 6, 
and T2 were 20. All of them were metastatic (N1 24, N2 2 cases). Presurgical 
biopsies of the tumors were obtained prior to the surgical intervention.   
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Case Age / Sex Site Diagnosis Follow-up 
1 71/F Tongue WD-OSCC T2N1 
2 60/M Buccal Mucosa PD-OSCC T2N1 
3 69/F Gingiva MD-OSCC T2N1 
4 70/M Tongue WD-OSCC T2N1 
5 79/F Buccal Mucosa MD-OSCC T2N1 
6 79/M Tongue PD-OSCC T2N1 
7 68/M Tongue PD-OSCC T1N1 
8 76/F Palate  MD-OSCC T2N1 
9 70/F Gingiva MD-OSCC T2N1 
10 81/F Gingiva PD-OSCC T2N1 
11 38/M Tongue MD-OSCC T1N1 
12 85/F Tongue MD-OSCC T2N1 
13 89/F Tongue MD-OSCC T2N1 
14 72/F Gingiva MD-OSCC T1N1 
15 70/M Gingiva MD-OSCC T2N1 
16 48/M Tongue MD-OSCC T2N1 
17 49/F Tongue PD-OSCC T2N1 
18 71/M Tongue PD-OSCC T1N1 
19 83/F Gingiva MD-OSCC T1N1 
20 60/M Tongue MD-OSCC T1N2 
21 71/M Tongue MD-OSCC T2N1 
22 71/M Tongue PD-OSCC T2N1 
23 75/F Buccal Mucosa WD-OSCC T2N1 
24 39/M Buccal Mucosa MD-OSCC T2N1 
25 74/F Tongue MD-OSCC T2N1 
26 48/M Tongue MD-OSCC T2N2 
 
 
Results were compared with 12 normal oral mucosa specimens collected during tooth 
extraction from non-smoker healthy patients. All information regarding the human 
material used in this study was managed using anonymous numerical codes. 
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- 12 non-progressive OPML from 12 patients (6 female and 6 male patients). Four 
were in the tongue, 4 from the buccal mucosa, 3 from gingiva, and 1 from the floor 
of the mouth. Seven OPML were low-grade dysplasia, 5 were moderate dysplasia.   
 
Case Age / Sex Site Diagnosis 
(dysplasia) 
Follow-up 
1 69/M Buccal Mucosa  Low grade  T0N0 
2 85/F Tongue Moderate grade T0N0 
3 90/M Floor of the mouth Moderate grade T0N0 
4 74/F Buccal Mucosa Low grade T0N0 
5 63/F Gingiva Low grade T0N0 
6 52/M Tongue Moderate grade T0N0 
7 79/F Buccal Mucosa Moderate grade T0N0 
8 67/F Gingiva Low grade T0N0 
9 73/M Gingiva Low grade  T0N0 
10 90/F Tongue Low grade T0N0 
11 42/M Buccal Mucosa Low grade T0N0 
12 53/M Tongue Moderate grade T0N0 
 
 
- 7 progressive OPMLs (4 female and 3 male patients). One was in the tongue, four 
from the buccal mucosa, two from gingiva. One OPML was low-grade dysplasia, 3 
were moderate dysplasia, 3 were high grade dysplasia.  
 
Case Age / Sex Site Diagnosis 
(dysplasia) 
Follow-up 
1 68/F Buccal Mucosa Moderate grade T2N1M0 
2 65/F Gingiva Low grade T1N2M0 
3 80/F Tongue Moderate grade T3N1M0 
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4 67/M Buccal Mucosa Moderate grade T1N0M0 
5 87/M Gingiva High grade T1N0M0 
6 61/F Buccal Mucosa High grade T1N0M0 
7 70/M Buccal Mucosa High grade T2N0M0 
 
Results were compared with 5 normal oral mucosa specimens collected during tooth 
extraction from non-smoker healthy patients.  
 
3.1.2 Statement of ethics 
All patients signed a written consent for molecular analysis and anonymous data 
publication for scientific studies, and all information regarding the human material used 
in this study was managed using anonymous numerical codes. 
 
3.1.3 MiRNA extraction  
Haematoxylin and eosin (H&E) sections from FFPE specimens were reviewed by a 
pathologist to select the more informative block. Four 20 µm-thick sections were cut 
followed by one H&E control slide. The tumor area selected for the analysis was marked 
on the control slide to ensure, whenever possible, greater than 90% content of neoplastic 
cells (avoiding necrosis and lymphocytes, normal epithelia). The four 20 µm-thick sections 
were manually dissected under microscopic guidance according to area selected on H&E 
and incubated in xylene for 3 minutes at 50°C and, after two rinses with ethanol, miRNAs 
were extracted using High Pure miRNA Isolation kit (Roche, Mannheim Germany), 
according to manufacturer's instructions. Quality and quantity of smallRNAs extracted 
from FFPE-dissected tissue were evaluated using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Waldbronn, Germany) and the Qubit fluorometer (Invitrogen, Carlsbad, 
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CA, U.S.A.). cDNA was obtained after a polyadenylation step and retrotranscription were 
performed using SuperScript III RT enzyme and a Universal RT Primer according to 
NCode miRNA first-strand cDNA synthesis and qRT-PCR Kit protocol (Invitrogen, 
Carlsbad, CA, U.S.A.). Fourteen miRNAs were selected for analysis, according to their role 
in cancer and data previously published in literature. MiR191 and RNU44 were used as 
endogenous controls. 
Each forward primer used corresponds to mature miRNA sequence according to miRBase 
database (http://microrna.sanger.ac.uk). Primers were modified with LNA (Locked 
Nucleic Acid) substitutions for increasing specificity and discriminating between miRNAs 
with a single base different nucleotide sequences. Universal reverse primer was provided 
by NCode miRNA first-strand cDNA synthesis and qRT-PCR Kit (Invitrogen, Carlsbad, 
CA, U.S.A.). 
Efficiency of each primer was tested by Real-Time PCR using serial dilutions (1:1, 1:25, 
1:50, 1:100) of a pool of RNA extracted by following cell lines: U-87 MG, MCF7 and 
LNCaP. A run of Real-Time PCR using as template a pool of female DNA (Promega, 
Madison, WI, U.S.A.) was performed to confirm that miRNAs primers were not able to 
amplify DNA. MiRNAs expression was evaluated using a AB7000 machine (Applied 
Biosystem, Foster City, CA, USA) and FastStart Taq Reagents Kit (Roche, Mannheim, 
Germany), with the following program: 2 minutes at 50°C, 4 minutes at 95°C and 37 cycles 
with annealing at 60°C for 30 seconds. GelStar stain (Lonza Bioscience, Rockland, ME, 
USA) was used as Real-Time detector. No template control for each miRNA was included 
in the reaction plate. All the reactions were performed in duplicate. 
The list of analyzed miRNA in FFPE specimens is the following: Let 7d, 7, 10a, 10b, 17, 20a, 
21, 26a, 31, 34a, 101, 137, 146a, 181b, 182, 196a, 200a, 200c 3p, 205 5p, 206, 221, 222, 345, 375, 
518b, 519d, 520g, 649. 
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3.1.4 Statistical analysis 
Expression values and fold-change were obtained by relative quantification and 
2−ΔΔCt method (Livak KJ, Schmittgen TD, 2001). Analysis of relative gene expression data 
was done using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
25: 402–408.), using DataAssist 2.0 Tool (Applied Biosystem, Foster City, CA, USA). 
Statistical analysis of miRNAs expression was performed using GraphPad Prism 5.0 tool.  
 
3.2 MiRNA in OSCC cell lines 
Two human oral tumor cell lines were analyzed: metastatic SCC2 cells and non-metastatic 
CAL27 cells. Cells were plated at 3x104 cells/cm2 in DMEM media supplemented with 
10% fetal bovine serum (FBS). All human tumor cells were collected and cultured from the 
Department of Molecular and Cell Biology of Boston University, Boston, USA.  
Using 15 Human Gene 2.0 ST arrays profiling human in OSCC SCC2 cells, with siRNAs-
mediated knockdown of DPAGT1, we identified miRNAs with altered expression using a 
cut-off of -1.7 fold change (FC) and a p-value<0.05. All RNA used in the study was 
isolated using High Pure miRNA Isolation kit (Roche, Mannheim Germany). A NanoDrop 
ND-100 spectrophotometer was used to quantify and observe the quality of the isolated 
RNA. Total RNA was collected and purified using RNeasy mini prep kit (Qiagen). cDNA 
synthesis was performed using 1 µg RNA and iScript cDNA synthesis kit according to 
manufacturer’s  protocol. qPCR was performed using Fast SYBR green enzyme (Applied 
Biosystems) and measured on real time PCR system. Extracted miRNAs were quantified 
by qPCR to determine their relationship to changes in DPAGT1 expression. Fold changes 
were calculated using the 2−ΔΔCt method. Statistical analysis was conducted with Prism 
software (GraphPad) using a two-tailed unpaired Student’s t test.   
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Six miRNAs were selected for functional characterization in non-metastatic OSCC CAL27 
cells transduced with lentiviral DPAGT1 and metastatic SCC2 cells with lentiviral 
knockdown of DPAGT1. Lentiviral transduction of DPAGT1 in cell lines induces 
expression of mesenchymal markers, notably Zeb1, Twist1 and Twist2, thus they were 
studied in this study.  
 
4. Results 
4.1 MiRNA expression in OPML  
The progressive OPML progressed to OSCC in the same site after a median period of 30 
months, while the non-progressive OPML remained free of further recurrence after a 
median follow-up period of six years.  
MiR191 and RNU44 were used as endogenous controls, as described previously, and they 
both revealed a good normalization score (1.6178) as indicated by DataAssist software. Of 
the miRNAs selected in this study, we have found a large number of miRNAs over-
expressed and very few miRNAs showed a down-regulation. In normal oral mucosa 
miRNAs were not found over or under-expressed.  
The following miRNAs passed the cut-off value of fold change:   
• Non-progressive OPLM: miR-137, miR-181b, miR-196a, miR-375, miR-520g, miR-
649; 
• Progressive OPLM: miR-137, miR-146a, miR-181b, miR-196a, miR-345, miR-375, 
miR-518b, miR-520g, miR-649. 
 
Significant results are related to miR-181b (p=0.0001) that exhibits an higher expression 
level in non-progressive OPML compared to the other groups; miR-649 (p=0.0057) shows 
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lower expression level in non-progressive OPML compared to progressive OPML 
(p=0.0334).  
 
  Non-
progressive 
OPML (FC) 
Non-
progressive 
OPML  
(p-value) 
 
Progressive 
OPML  
(FC) 
Progressive 
OPML  
(p-value) 
Let7-d 1.184 0.7578 1.0649 0.859 
miR-137 4.2758 0.1849 3.1068 0.0632 
miR-146a 1.8982 0.4523 329.146 0.3458 
miR-181b 18.5864 0.0001 12.7098 0.1118 
miR-196a 97.5375 0.2995 75.2262 0.1113 
miR-21 1.2084 0.6031 1.2095 0.6842 
miR-221 1.8988 0.3118 1.4598 0.2986 
miR-222 1.1502 0.7153 1.1944 0.5798 
miR-345 0.6508 0.5492 222.926 0.3562 
mir-375 4.2758 0.1849 10.0206 0.1024 
miR-518b 1.8677 0.2651 409.851 0.3479 
miR-520g 695.455 0.4615 193.086 0.2288 
miR-649 3.2471 0.0057 7.4628 0.0334 
miR-191 1.1973 0.5543 2.4957 0.2502 
 
Considering differences between non-progressive and progressive OPMLs, the fold 
change expression of miR-146a, miR-345, miR-518b and miR-649 revealed a marked 
difference.  
The marked over-expression of these miRNAs compared to normal controls and non-
malignant oral lesions may indicate that the gradual genetic alterations, that lead a 
premalignant lesion to transform into cancer and metastasis, is mediated and regulated by 
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miRNAs. In particular miR-649 results the best candidate of the malignant progression of 
progressive OPML.  
 
4.2 MiRNA expression in OSCC 
The 26 cases of non-metastatic OSCC remained free of further recurrence and metastasis 
after a median follow-up period of 5 years. 
Significant data were obtained for miR-21 (p=0.048) and miR-137 (p=0.048) between 
metastatic OSCC versus non-metastatic OSCC. In particular miR-21 was overexpressed 
while miR-137 resulted under-expressed.  
 Fold Change  P-value (<0.05) 
miR-21 2.594 0.048 
miR-137 0.242 0.048 
 
Regarding oral presurgical biopsies significant data were obtained for the overexpression 
of miR-21  (p=0.036) and under-expression of miR-10a (p=0.03). 
 Fold Change  P-value (<0.05) 
miR-21 4.22 0.0036 
miR-10a 0.77 0.03 
 
 
Significant data were obtained for miR-21 (p=0.048), miR-101 (p=0.005), miR-200a 
(p=0.019), miR-206 (p=0.013), miR-221 (p=0.042) and miR-345 (0.0006) between metastatic 
OSCC versus normal tissues. All of the miRNAs resulted over-expressed except for 
miR345 that was under-expressed.  
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 Fold Change  P-value (<0.05) 
miR-21 4.38 0.005 
miR-101 2.919 0.014 
miR-200a 4.256 0.019 
miR-206 152.35 0.013 
miR-221 1.776 0.042 
miR-345 0.297 0.0006 
 
 
 
4.2 MiRNA expression in OSCC cell lines 
Twenty-five significant miRNAs related to DPAGT1 knockdown were founded in the 
arrays. Approximately 1000 miRNAs were included in the array.  
 
miRNA Fold Change (cutoff - 1.7) p-value (<0.05) 
21 2.7 6.7x10-10 
23a 2.3 6.3x10-5 
24.1 2.5 4.9x10-7 
24.2 4.8 1.2x10-8 
27a 3.2 1.4x10-7 
31 2.5 1.2x10-4 
141 1.7 1.9x10-2 
181b-1 2.6 1.2x10-3 
200c -2.1 2.4x10-3 
205 -2.8 1.4x10-4 
221 7.1 3.4x10-7 
222 2.3 5.8x10-6 
224 1.9 4.3x10-2 
503 -1.9 4.3x10-4 
570 1.7 3.3x10-4 
573 2.3 3.7x10-3 
590 2.3 9.9x10-4 
612 3 1.5x10-4 
711 1.7 1.3x10-3 
936 2.5 2.2x10-6 
1204 1.7 4.8x10-3 
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3064 1.9 5.8x10-5 
3661 1.8 7.2x10-4 
3671 2.1 7.6x10-3 
5047 2.4 1.7x10-5 
 
Of them, six miRNAs were selected based on their reported roles in EMT. They included: 
miR-21, miR-181b, miR-200c, miR-205, miR-221, miR-222.  We extracted and measured 
their expression in CAL27 cells with induced expression of DPAGT1 and in SSC2 cells 
with silenced expression of DPAGT1. 
In SCC2 cells with DPAGT1 knockdown, miR-200c was overexpressed (FC=11.5; p=0.04) 
while in CAL27 cells overexpressing DPAGT1, miR-200c was reduced (FC=0.47; p=0.01). 
 
 
 
 
 
EMT-associated transcription factors, in particular ZEB1, expression were found down-
regulated in SCC2 cells with DPAGT1 knockdown and up-regulated in CAL27 cells 
transduced with DPAGT1. Moreover, when miR-200c was down-regulated, Vimentin and 
N-cadherin (markers of EMT) were highly expressed together with Twist 1-2 and ZEB1. 
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The microscope imagine shows the different form of the in vitro cells, in particular cells 
with DPAGT1 overexpression are more elongated and detached each other, thus similar to 
mesenchymal cells, differently from the epithelial cells of the control. On the other hand, 
miR-200c overexpression resulted in down-regulation of EMT markers together with 
down-regulation of ZEB1 and Twist 1. Imagine from the microscope describe the reverse 
transformation from mesenchymal cells to cuboidal, attached cells like the epithelial cells. 
 
 
 
 
 
The following figure described the algorithm between miR-200c, DPAGT1 and ZEB1 
related to the initiation of EMT. In particular, miR-200c acts as a tumor suppressor miRNA 
stopping ZEB1 in the initiation of EMT. The DPAGT1 gene shows an oncogenic role by 
suppressing miR-200c and inducing EMT. Further studies need to reveal if miR-200c can 
inhibit DPAGT1 gene directly.  
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5. Discussion  
 
Histological diagnosis cannot evaluate the risk of malignant transformation. Thus, miRNA 
has revealed to be good biomarkers for the management of these lesions. It seems that 
miRNAs can regulate important genetic steps that lead a dysplastic cell to transform into a 
cancer cell. In the present study, we explore the expression of miRNA in the malignant 
transformation of OPML and in aggressive OSCC cells and tumor samples. 
 
MiRNA that revealed a diagnostic role and thus can be used as biomarker to differentiate 
non-progressive OPML to progressive OPML was miR-649.  
MiR-649 was found over-expressed in OPML at high-risk of malignant transformation 
compared to non-progressive OPML. The marked over-expression of this miRNA 
compared to normal controls and non-malignant oral lesions may indicate that the 
gradual genetic alterations, that lead a premalignant lesion to transform into cancer is 
mediated and regulated by this miRNA. 
In literature several miRNAs are described as over-expressed in OPML [47-49, 73, 74]. 
However, the most consistent study that describes a miRNA signature associated to 
progressive OPML is the study of Cervigne et al. [50]. They examined the miRNA 
expression in 29 leukoplakias that progressed to OSCC compared to 4 non-progressive 
leukoplakias and 7 normal tissues, and they found a large number of altered miRNAs. In 
particular, miR-21, 181b, 345, 146a, 518b, 520g, 649, 184 showed an increased expression 
during the progression to OSCC. The authors showed that some of the genetic alterations 
in OSCC are earlier expressed in the same-site leukoplakia.  
Interestingly regarding miR-181b, Cervigne et al. reported an overexpression of this 
miRNA in progressive leukoplakias. However Yang et al. [48] revealed that miR-181b was 
found under-expressed in progressing leukoplakias compared to non-progressing. Our 
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data show a significant overexpression of miR-181b in non-progressive OPML in 
accordance with the article of Yang et al. These controversial data describe an uncertain 
role for miR-181b in OPML that need further studies.  
In our results this miRNA showed a marked difference in terms of fold change between 
lesions that transformed into cancer and lesions that remained stable in a long-term 
follow-up period. Our study corroborates previous data reported by other authors [47, 50, 
73] and seeks to underline the importance of introducing miRNAs in the all-day clinical 
practice of oral surgeons and pathologist in order to avoid the development of OSCC. 
MiRNAs represent important regulators of epigenetic expression and can be used for the 
early detection of OPML at high-risk of malignant transformation. 
 
Regarding OSCC samples, we focused on T1 and T2 tumors because they present a better 
prognosis and nodal spread is usually confined to lymph nodes. Therefore the reason was 
to minimize the biological variations and to find biomarkers correlated to the early 
metastatic tumors. Thus, a diagnosis made by a miRNA biomarker at early stage or N1 
stage can increase the survival expectation of the patient. 
Our results showed a significant difference between miRNAs in T1 and T2 metastatic 
tumors and T1 and T2 tumors free of metastasis in more than 5 years. In particular, miR-21 
was found overexpressed in aggressive OSCC that had metastasis in one or more cervical 
lymph nodes. MiR-21 is an established oncogenic miRNA that targets tumor-suppressing 
genes TPM1 and PTEN [55, 75]. Mir-21 was found over-expressed in squamous cell 
carcinoma of the tongue, and in progressive OPMLs [47, 48, 50]. This oncogenic miRNA 
promotes the tumor invasion of SCC of the tongue via the Wnt/β-catenin pathway by 
targeting tumor suppressor DKK2 [56]. MiR-21 was also involved in EMT in human 
bronchial epithelial cells and hepatocytes [58, 76]. 
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Of interest, the miR-21 over-expression in presurgical biopsies revealed an important role 
of miRNA analysis directly prior to the surgery in order to make a correct diagnosis and 
orientate the prognosis. Mir-10a was found under-expressed in presurgical biopsies but 
not in OSCC samples. Very few studies are present in literature describing the role of miR-
10a in oral cancer, thus further research is necessary.  
On the other hand, we showed a down regulation of miR-137 in tumor samples, 
suggesting a tumor suppressor role in the events that lead to the metastasis as previously 
reported in literature [77]. Mir-137 seems to inhibit the mesenchymal biomarkers N-
cadherin, vimentin and Snail expression indicating a suppressing role in EMT. 
Regarding the miRNAs found in OSCC differently from normal oral tissues, we are not 
stupefied to see more overexpressed miRNAs because of their oncological role to promote 
OSCC. Mir-101 is described as a tumor suppressor miRNA, it is underexpressed in OSCC 
tissues and cell lines and inversely related to ZEB1 expression [78]. MiR-200a belongs to a 
different cluster of the miR-200 family (differently from miR-200c) but very few articles are 
described in literature about oral tissues, as well as about miR-345.  
MiR-221 is known to be involved in tumorigenesis in several neoplasms, in particular in 
OSCC it is correlated to the growth of the tumor and p27 and p57 might be the targets of it 
[79]. 
 
Several studies reveal a miRNA expression in patients with metastasis of OSCC. Mir-29b, 
miR-155-5p miR-372, miR-373 are higher expressed in OSCC patients with lymph-node 
metastasis and thus they act as oncomirs in the malignant progression of OSCC [80-82]. 
Only two studies, similar to ours, reported a comparison between miRNA expression in 
patients with and without lymph node metastasis. In one article, the authors compared 20 
metastatic OSCC with 17 non-metastatic OSCC and found 31 miRNAs differently 
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expressed, in particular miR-29a, miR-29c and miR-140-3p are involved in the 
downregulation of their specific target genes [83]. The other article reported an over-
expression of miR-31 and miR-130b in non-metastatic samples, while miR-181 and miR-
296 are over-expressed in metastatic tumors [84]. Regarding the discovery of miRNA in 
presurgical biopsies very rare oncological articles are reported in the literature. To best of 
our knowledge, only one article reported a miRNA expression in FFPE lymph nodes and 
fine-needle aspiration biopsies of OSCC patients. Mir-203 and miR-205 were found highly 
expressed in metastatic lymph nodes and showed high accuracy in fine-needle aspiration 
biopsies [85]. 
Our data suggest an important role of miR-21 both in oral presurgical biopsies and oral 
tissues as a prognostic factor in discriminating metastatic from non-metastatic OSCC. This 
result represents an important finding because no other studies describe a miRNA 
expression starting from biopsies and confirmed in tissues.  
 
In OSCC cell lines, our results show that miR-200c is inversely related to DPAGT1 
expression and suggest that EMT and increased proliferation of complex N-glycans in 
OSCC are driven by changes by this miRNA. We identified ZEB1 as a predominant 
marker of EMT, in particular a significant correlation was observed between high ZEB1 
expression and tumor cell proliferation associated with DPGAT1 overexpression. We 
demonstrated that the inhibition of ZEB1 and DPAGT1 in OSCC cell lines lead to 
significant inhibition of cell invasion in vitro guided by the overexpression f miR-200c.  
 
The miR-200 family consists of five members, which form two clusters. MiR-200b, miR-
200a and miR-429 are clustered on human chromosome 1, whereas miR-200c and miR-141 
are grouped on chromosome 12, with each cluster expressed as a polycistronic transcript. 
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Binding specificities differ within the miR-200 family, with seed sequences differing 
between miR-200a-141 (subgroup I) and miR-200b-200c-429 (subgroup II) [86]. 
We have found that repression of ZEB1 by miR-200c resulted in reduced expression of the 
key mesenchymal markers, vimentin and fibronectin, and acquisition of an epithelial 
phenotype.  
MiR-200 family members have subsequently been studied in a number of 
EMT-related in vitro model systems. During induction of EMT in MDCK cells with either 
TGF-b or ectopic expression of the protein tyrosine phosphatase Pez, the miR-200 family 
and E-cadherin were repressed in parallel with an increase in ZEB1 and ZEB2 expression 
[87]. The ability to induce an EMT was dependent upon repression of the miR-200 family 
and induction of ZEB1 and ZEB2 expression. Conversely, a MET could be induced by 
expression of the miR-200 family in cells that were originally mesenchymal in nature. 
These results confirm that the miR-200 family represses ZEB1 expression and 
consequently inhibits the progression of an EMT by establishing and maintaining an 
epithelial phenotype. The repression of ZEB expression by miRNA-200 family is direct, 
and occurs as a result of the miRNA binding to eight and nine sites in the 3 UTRs of ZEB1 
and ZEB2 mRNA [69]. 
Data suggest that the majority, if not all, epithelial cells express high levels of the miR-200 
family, which directly repress ZEB1 and ZEB2 and so enable the expression of E-cadherin. 
However, if an extracellular signal stimulates the expression of ZEB1, the miR-200 family 
is suppressed allowing EMT to proceed. 
 
Together with ZEB1 expression we have found Twist1 expression. Twist1 is a highly 
conserved, basic helix-loop-helix transcription factor mapped at 7q21.2, has a bifunctional 
role, acting as an activator or a repressor, depending on post-translational modifications 
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and physiologic contexts [88, 89]. Twist1 induces gene transactivation through cisbinding 
to E-box regulatory regions, which are present in several target genes, and this involves 
complex homodimerization and heterodimerization mechanisms regulated by protein 
phosphorylation [89]. In the case of gene repression, Twist1 can repress genes by 
regulating chromatin remodeling through histone acetyltransferase-dependent=histone 
deacetylase-dependent mechanisms and through the inhibition of DNA binding activity of 
transcription factors [88]. The implication of Twist1 in cell migration is attributed 
primarily to its ability to contribute to EMT, through the down-regulation of E-cadherin 
and the upregulation of mesenchymal markers like vimentin, fibronectin, and N-cadherin 
[90, 91]. Previous studies have indicated that Twist1 promotes cell proliferation, migration, 
and expression of a primitive ECM, thus promoting an undifferentiated state [90]. In 
addition, Twist1 contributes to the EMT phenotype, which has been associated with 
resistance to chemotherapy and relapses [91]. 
 
  
6. Conclusions 
	  
The progressive accumulation of genetic and epigenetic modifications leads the cell to 
undergo the neoplastic transformation. Thus, the use of molecules that regulate these 
processes are becoming important to prevent the genesis and growth of OSCC. 
The overespression of miR-21 and downregulation of miR-137 may be used as prognostic 
biomarkers to differentiate metastatic OSCC between non-metastatic OSCC, while miR-
649 can be used as a biomarker to prevent the malignant transformation of OPML. The 
miR-21 overexpression in presurgical biopsies of metastatic OSCC seems a useful 
biomarker to differentiate metastatic OSCC from non-metastatic OSCC. 
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In vitro data about tumor suppressor miR-200c must be tested in surgical samples and if 
good data will be obtained it may be used as a therapeutic option.  
Our findings suggest that some miRNAs are correlated to an invasive behavior in OSCC 
and in OPML. The detection of these novel biomarkers can guide the surgeon to prevent 
the development of the tumor and lymph-node metastasis and to a better management of 
the patients. 
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